Skip to content
10-Q

Quarterly Report

Landos Biopharma, Inc.

0000950170-24-056311

← back to feed
Filed
May 9, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 3, 2024 3.13M sh
Shares Diluted Q1 2024 · Mar 31, 2024 6.21M sh
Shares Diluted restated Q1 2024 · Mar 31, 2023 6.48M sh
Stock Repurchased Q1 2024 · Mar 31, 2024 $0
Stock Repurchased Q1 2024 · Mar 31, 2023 $3M
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$8.5M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$8.17M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $29M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $37.5M
Stockholders Equity Q1 2024 · Mar 31, 2024 $23.15M
Stockholders Equity Q1 2024 · Dec 31, 2023 $31.79M
Stockholders Equity Q1 2024 · Mar 31, 2023 $47.02M
Stockholders Equity Q1 2024 · Dec 31, 2022 $39.13M
Current Liabilities Q1 2024 · Mar 31, 2024 $6.74M
Current Liabilities Q1 2024 · Dec 31, 2023 $6.25M
Total Liabilities Q1 2024 · Mar 31, 2024 $6.74M
Total Liabilities Q1 2024 · Dec 31, 2023 $6.25M
Current Assets Q1 2024 · Mar 31, 2024 $29.9M
Current Assets Q1 2024 · Dec 31, 2023 $38.04M
Total Assets Q1 2024 · Mar 31, 2024 $29.9M
Total Assets Q1 2024 · Dec 31, 2023 $38.04M
Eps Diluted Q1 2024 · Mar 31, 2024 −$1.43
Eps Diluted restated Q1 2024 · Mar 31, 2023 −$0.93
Eps Basic Q1 2024 · Mar 31, 2024 −$1.43
Eps Basic restated Q1 2024 · Mar 31, 2023 −$0.93
Sga Expense Q1 2024 · Mar 31, 2024 $6.14M
Sga Expense Q1 2024 · Mar 31, 2023 $3.15M
Rd Expense Q1 2024 · Mar 31, 2024 $3.15M
Rd Expense Q1 2024 · Mar 31, 2023 $3.33M
Net Income Q1 2024 · Mar 31, 2024 −$8.9M
Net Income Q1 2024 · Mar 31, 2023 −$6.03M
Operating Income Q1 2024 · Mar 31, 2024 −$9.3M
Operating Income Q1 2024 · Mar 31, 2023 −$6.48M